Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Alpha Tau Medical Ltd DRTS

Alternate Symbol(s):  DRTSW

Healthcare Biotechnology
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical... see more

Recent & Breaking News (NDAQ:DRTS)

Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium

GlobeNewswire December 4, 2025

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

GlobeNewswire December 2, 2025

Alpha Tau to Participate in December Investor Conferences

GlobeNewswire December 1, 2025

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 20, 2025

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

GlobeNewswire November 11, 2025

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

GlobeNewswire October 21, 2025

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

GlobeNewswire September 2, 2025

Alpha Tau to Participate in Five September Investor Conferences

GlobeNewswire August 27, 2025

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 11, 2025

Alpha Tau to Present at Jefferies Global Healthcare Conference

GlobeNewswire May 28, 2025

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire May 19, 2025

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

GlobeNewswire May 12, 2025

Alpha Tau to Participate in May Investor Conferences

GlobeNewswire May 6, 2025

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

GlobeNewswire April 28, 2025

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

PR Newswire April 28, 2025

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

GlobeNewswire April 2, 2025

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire March 12, 2025

Alpha Tau to Participate in March Investor Conferences

GlobeNewswire February 27, 2025

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

GlobeNewswire February 24, 2025

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

GlobeNewswire February 3, 2025

Podcasts